Cooper Companies (COO) PT Set at $282.00 by Oppenheimer

Cooper Companies (NYSE:COO) has been assigned a $282.00 price target by analysts at Oppenheimer in a report released on Friday. The firm currently has a “hold” rating on the medical device company’s stock. Oppenheimer’s target price would suggest a potential upside of 10.04% from the company’s previous close.

COO has been the subject of several other research reports. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating in a report on Monday, October 1st. BMO Capital Markets raised their price target on Cooper Companies from $294.00 to $306.00 and gave the stock a “positive” rating in a report on Friday. Wells Fargo & Co raised their price target on Cooper Companies from $290.00 to $295.00 and gave the stock an “outperform” rating in a report on Monday, November 12th. ValuEngine raised Cooper Companies from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Finally, Jefferies Financial Group raised their price target on Cooper Companies to $305.00 and gave the stock a “buy” rating in a report on Friday. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $284.50.

COO traded down $20.76 on Friday, hitting $256.27. The company had a trading volume of 335,108 shares, compared to its average volume of 312,680. Cooper Companies has a 12-month low of $216.47 and a 12-month high of $283.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54. The firm has a market capitalization of $13.51 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77.

Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, December 6th. The medical device company reported $2.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.96 by ($0.09). Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The company had revenue of $651.50 million during the quarter, compared to analysts’ expectations of $645.25 million. During the same quarter last year, the firm earned $2.65 EPS. Cooper Companies’s revenue for the quarter was up 16.0% on a year-over-year basis. As a group, sell-side analysts expect that Cooper Companies will post 11.61 EPS for the current year.

In related news, VP Randal Golden sold 1,731 shares of Cooper Companies stock in a transaction dated Thursday, September 27th. The stock was sold at an average price of $275.86, for a total transaction of $477,513.66. Following the completion of the sale, the vice president now owns 1,154 shares of the company’s stock, valued at $318,342.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director A Thomas Bender sold 7,150 shares of Cooper Companies stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $269.36, for a total value of $1,925,924.00. Following the sale, the director now directly owns 18,355 shares of the company’s stock, valued at approximately $4,944,102.80. The disclosure for this sale can be found here. Insiders have sold 20,691 shares of company stock valued at $5,527,869 in the last ninety days. Corporate insiders own 1.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Cooper Companies by 0.6% during the third quarter. Vanguard Group Inc. now owns 5,041,468 shares of the medical device company’s stock worth $1,397,243,000 after purchasing an additional 31,280 shares during the period. Janus Henderson Group PLC lifted its holdings in Cooper Companies by 23.8% in the second quarter. Janus Henderson Group PLC now owns 2,618,690 shares of the medical device company’s stock valued at $616,595,000 after acquiring an additional 502,783 shares during the period. Frontier Capital Management Co. LLC lifted its holdings in Cooper Companies by 13.5% in the third quarter. Frontier Capital Management Co. LLC now owns 937,389 shares of the medical device company’s stock valued at $259,797,000 after acquiring an additional 111,828 shares during the period. FIL Ltd lifted its holdings in Cooper Companies by 16.1% in the third quarter. FIL Ltd now owns 815,901 shares of the medical device company’s stock valued at $226,127,000 after acquiring an additional 113,054 shares during the period. Finally, Bessemer Group Inc. lifted its holdings in Cooper Companies by 0.8% in the third quarter. Bessemer Group Inc. now owns 761,555 shares of the medical device company’s stock valued at $211,064,000 after acquiring an additional 5,828 shares during the period.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Read More: Benefits of owning preferred stock

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply